List view / Grid view

Research & Development (R&D)

Roche pays $3.5bn for 89bio and its potential best-in-disease treatment MASH drug

18 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

The deal with the US biopharma could help address metabolic dysfunction-associated steatohepatitis, one of the most prevalent comorbidities of obesity.

news

GSK outlines $30bn, five-year plan for R&D and manufacturing in the US

17 September 2025 | By Dominic Tyer (European Pharmaceutical Review)

The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.

news

Novartis builds on Monte Rosa collaboration with $5.7 billion deal

16 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company’s pipeline.

news

ICH to implement M14 Guideline for post-marketing safety submissions

15 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

The ICH Assembly’s decision supports progress in promoting international standards for safety assessment of medicines.

news

Pharma’s UK dissatisfaction mounts as Merck & Co axes $1.3bn expansion

15 September 2025 | By Dominic Tyer (European Pharmaceutical Review)

Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.

in-line quality monitoring pharmaceutical

news

In-line pharma monitoring system developed for tablet quality inspection

12 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

The novel approach could enhance quality testing applications in pharmaceutical manufacturing.

news

FDA approves first-of-a-kind intravesical drug delivery system for bladder cancer

10 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.

news

FDA to modernise review process for developers of ultra-rare diseases

5 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.

news

Roche en route to first continuous delivery treatment for nAMD in Europe

4 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).

news

Amgen to build $600m science and innovation centre in the US

4 September 2025 | By Dominic Tyer (European Pharmaceutical Review)

The new Thousand Oaks, California facility will incorporate advanced automation and digital capabilities.

news

Merck’s health business gains new Global Head of R&D

3 September 2025 | By Dominic Tyer (European Pharmaceutical Review)

David Weinreich will also serve as its Chief Medical Officer and arrives at the German pharmaceutical group with experience from Amgen, Bayer and Regeneron.

close up of a mass spectrometer device with blurred lab background - idea of mass spectrometry

news

Demand for AI-integration propelling mass spectrometry growth

3 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.

news

FDA waives trial requirement for Stelera biosimilar, easing the copycat’s path

2 September 2025 | By Catherine Eckford (European Pharmaceutical Review)

First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.

webinar

The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology

2 September 2025 | By FUJIFILM Wako Europe GmbH

Watch this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.

news

Roche touts ‘best-in-disease’ potential for anti-hypertensive zilebesiran

1 September 2025 | By Dominic Tyer (European Pharmaceutical Review)

While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Research & Development (R&D)